FDA grants clearance for radiation oncology tool to calculate absorbed dose of radionuclides

Don’t confirm RFK Jr. for HHS, 77 Nobel laureates urge the Senate

Robert F. Kennedy Jr., President-elect Donald Trump’s choice for HHS secretary, is unfit for that role and should not be confirmed, 77 Nobel laureates said in a letter to members of the U.S. Senate.

December 13, 2024

Vol.50 No.46

By Yiqing Wang

Drugs & Targets

FDA approves durvalumab for LS-SCLC

FDA approved durvalumab (Imfinzi, AstraZeneca) for adults with limited-stage small cell lung cancer whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy.

December 13, 2024

Vol.50 No.46

In Brief

UT Southwestern brings radiation oncology to $177M campus in Fort Worth Medical District

To meet the growing demands for cancer treatment in Tarrant County and surrounding areas, UT Southwestern Medical Center is expanding its cancer services in the Fort Worth Medical District with construction of a two-story radiation oncology campus that will house the city’s first MRI-guided precision radiation treatment.

December 06, 2024

Vol.50 No.45

Clinical Roundup

ASTRO survey finds prior authorization delays lead to serious harm for people with cancer

A new nationwide survey of more than 750 radiation oncologists confirms that prior authorization harms people with cancer by causing treatment delays, abandoned treatments, hospitalizations and patient deaths.

December 06, 2024

Vol.50 No.45

Drugs & Targets

FDA grants accelerated approval to zenocutuzumab-zbco for NSCLC and pancreatic adenocarcinoma

FDA has granted accelerated approval to zenocutuzumab-zbco (Bizengri) for adults

December 06, 2024

Vol.50 No.45

Clinical Roundup

NCCN updates CML treatment guidelines following FDA approval of Scemblix for newly diagnosed patients

The National Comprehensive Cancer Network updated its chronic myeloid leukemia treatment guidelines, recommending Scemblix (asciminib) for the treatment of adults with newly diagnosed Ph+ CML-CP as a category 1-preferred.

November 22, 2024

Vol.50 No.44

FDA grants clearance for radiation oncology tool to calculate absorbed dose of radionuclides

YOU MAY BE INTERESTED IN

Don’t confirm RFK Jr. for HHS, 77 Nobel laureates urge the Senate

FDA approves durvalumab for LS-SCLC

UT Southwestern brings radiation oncology to $177M campus in Fort Worth Medical District

ASTRO survey finds prior authorization delays lead to serious harm for people with cancer

FDA grants accelerated approval to zenocutuzumab-zbco for NSCLC and pancreatic adenocarcinoma

NCCN updates CML treatment guidelines following FDA approval of Scemblix for newly diagnosed patients

Renew today!

Subscriber content

Never miss an issue!

Login